Phase 3 N=140 Evaluation in the Treatment of Neuropathic Pain Post Breast Surgery
Breast Cancer Patient
Primary: Change in Neuropathic Pain Score at 2 Months (Numeric Rating Scale 0-10) — 4.1; 4.6 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=104 Neuropathic Pain Syndrome Patient Study (MK-0000-072)
Neuralgia, Postherpetic · Diabetic Neuropathy · Painful Small-Fiber Neuropathy
Primary: Daily Evening Patient Reported Pain Intensity Scores — 0.14; 1.57 Units on a Scale — p=0.003
N/A N=22 Nociceptive Pain Fiber Response
Painful Peripheral Diabetic Neuropathy
Primary: Changes in Small Nerve Fiber Density by Assessment of a Skin Biopsy Comparing Baseline to Day 60 — .1; .1 nerve fibers / mm squared
N/A N=47 Cognitive Behavioral Therapy for Diabetic Neuropathic Pain
Diabetic Peripheral Neuropathic Pain
Primary: Numeric Rating Scale (NRS) Pain Intensity — -0.83; -0.45 units on a scale — p=0.47
Phase 3 N=75 Neuropathic Pain Management
Diabetic Neuropathies · Polyneuropathies
Primary: Mean Neuropathic Pain Score at Visit 3 (Week 1) — 51.00; 50.70 Units on a Scale
N/A N=34 Lidocaine for Diabetic Peripheral Neuropathy
Diabetes · Peripheral Neuropathy · Pain
Primary: Change in Spontaneous Pain at 60-120 Minutes After Lidocaine Infusion Initiated (Assessed on 0-10 NRS) — 33; 51 percentage of pain change from baseline — p=0.03
Phase 4 N=121 Pregabalin Treatment Of Peripheral Neuropathic Pain Associated With Diabetic Peripheral NeP (DPN), Postherpetic Neuralgia (PHN), HIV-related NeP (HIV), and Chemotherapy Induced NeP
Diabetic Peripheral Neuropathic Pain (DPN) · Postherpetic Neuralgia (PHN) · HIV-related Neuropathic Pain (HIV)
Primary: Change From Baseline to End of Treatment (EOT) in Weekly Mean Pain Score on the Daily Pain Rating Scale (DPRS) — -3.8 scores on scale — p=< 0.0001
Phase 3 N=256 Efficacy Study Measuring the Impact of Pregabalin on Peripheral Neuropathic Pain.
Neuropathic Pain
Primary: Neuropathic Pain in Subjects With Peripheral Neuropathic Pain Conditions During the Double-blind Phase — 2.84; 3.62 score on scale — p=0.0018
N/A N=53 The Effect of Neurontin on Pain Management in the Acutely Burned Patient
Pain · Burn Injury
Primary: Opioid Consumption Between the Treatment and the Control Groups (Morphine Equivalents) — 7.0; 6.7 morphine equivalents — p=<0.05
Phase 3 N=246 A Study of Sativex® for Pain Relief of Peripheral Neuropathic Pain, Associated With Allodynia
Pain · Peripheral Neuropathy
Primary: Change From Baseline in Mean Peripheral Neuropathic Pain on a 0-10 Numerical Rating Scale (NRS) Score at the End of Treatment (15 Weeks) — -1.36; -0.84 units on a scale…
N/A N=161 Symptom Management Efficacy Study to Reduce Distal Neuropathic Pain
Neuropathic Pain · HIV Neuropathy · HIV/AIDS
Primary: Gracely Pain Scale (GPS) — -2.51; -1.96; -2.38; -0.99 GPS pain score on a scale
Phase 3 N=542 Placebo-controlled Safety and Efficacy Study of Pregabalin in Subjects With Post-traumatic Peripheral Neuropathic Pain
Neuropathic Pain
Primary: Baseline Mean Pain Score — 6.41; 6.54 units on a scale
N/A N=7 Percutaneous Peripheral Nerve Stimulation (Neuromodulation) for Postoperative Analgesia
Postoperative Pain
Primary: Change From Baseline of Surgical Site Pain Level (NRS) at Rest [Percentage of Baseline Pain] — 64; 100; 55; 69 percentage of baseline
Phase 3 N=240 Pregabalin Peripheral Neuropathic Pain Study
Diabetic Neuropathies · Neuralgia
Primary: Daily Pain Rating Scale (DPRS)- Mean Pain Score (ITT Population) — 4.63; 5.13 score on scale — p=0.049
Phase 2 N=273 A Study for Treatment of Pain in Patients With Diabetic Neuropathy.
Diabetic Neuropathy, Painful
Primary: Change From Baseline in Weekly Mean 24-hour Average Pain Severity (APS) Score at 5 Weeks — -2.08; -2.22; -2.45; -2.42 units on a scale
Phase 2 N=22 Clonidine Versus Adenosine to Treat Neuropathic Pain
Pain
Primary: Number Meeting Success Criterion — 10; 5; 0 participants meeting success criterion — p=>0.05
Phase 3 N=125 A Study of Sativex® for Relief of Peripheral Neuropathic Pain Associated With Allodynia.
Pain · Peripheral Neuropathy
Primary: Change From Baseline in the Mean Daily Peripheral Neuropathic Pain on a 0-10 Numerical Rating Scale Score During the Last Seven Days of Treatment (End of Treatment)…
N/A N=15 Neuropathic Pain in Pregnancy
Pain · Pregnancy
Primary: Change From Baseline Visual Analogue Scale for Pain — -0.57; -14.4 score on a scale
Phase 3 N=44 Brivaracetam to Reduce Neuropathic Pain in Chronic SCI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Spinal Cord Injuries · Neuropathic Pain
Primary: The International Spinal Cord Injury Pain Data Set (ISCIPBDS) (Version 2.0) - Change in Average Worst Neuropathic Pain Intensity — -0.5; -0.5 points
N/A N=86 Pregabalin for the Treatment of Pain After Posterior Spinal Fusions
Lumbar Spinal Fusions
Primary: Patient Controlled Analgesia (PCA) Hydromorphone Usage — 44; 39 mL
N/A N=8 Peripheral Sensory Input in Central Post Stroke Pain (CPSP)
Central Post Stroke Pain
Primary: Reduction in Spontaneous Pain Intensity After a Peripheral Nerve Block. — 6.5; 0.0 units on a scale
Phase 2 N=452 Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
Diabetic Peripheral Neuropathy
Primary: Mean Change From Baseline to Week 5 in Average Daily Pain Score (ADPS) Following Treatment With DS-5565 Compared to Pregabalin and Placebo — -1.86; -1.79; -2.04; -2.32…
Phase 4 N=368 P4 (Pregabalin for Peripheral Posttraumatic Pain)
Neuralgia
Primary: Weekly Mean Pain Score at End of Treatment (Week 8) From Daily Pain Diary — 4.61; 5.23 score on a scale — p=0.010
Phase 2 N=301 Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
Diabetic Peripheral Neuropathy
Primary: Numeric Rating Scale (NRS) Average Pain Intensity — -1.50; -1.61; -1.15; -1.23 score on a scale
N/A N=35 Effects of Pennsaid on Clinical Neuropathic Pain
Neuralgia · Postherpetic Neuralgia · Reflex Sympathetic Dystrophy
Primary: VAS After Treatment — 4.9; 5.6 Visual Analog Scale — p=.04
N/A N=16 Postoperative Peripheral Nerve Stimulation for Management of Post-amputation Pain
Phantom Limb Pain · Postoperative Pain · Neuroma
Primary: Average Phantom Limb Pain (PLP) Score — 4.1; 3.1; 2.2; 3.0 score on a scale
Phase 2 N=24 Brivaracetam to Reduce Neuropathic Pain in Chronic Spinal Cord Injury
Spinal Cord Injuries
Primary: Brief Pain Inventory, Worst Pain — 8.9; 9.7 score on scale
N/A N=254 Neuromodulatory Treatments for Pain Management in TBI
Chronic Pain · Traumatic Brain Injury · Posttraumatic Stress Disorder
Primary: Change in Self-reported Pain Intensity — -1.02; -0.78; -1.03 score on a scale — p=0.2852
Phase 2 N=11 The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain
Neuropathic Pain
Primary: Opioid Use — 101.24; 104.56 morphine equivalent dose
Phase 3 N=297 A Study of Sativex® for Pain Relief Due to Diabetic Neuropathy
Pain · Diabetic Neuropathy
Primary: The Change From Baseline in Mean Diabetic Neuropathy Pain 0-10 Numerical Rating Scale Score at the End of Treatment (Average of Last 7 Days Treatment) — -1.67; -1.55…